Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature


Ongoren S., Eskazan A. E. , Suzan V., Savci S., Ozunal I. E. , Berk S., et al.

HEMATOLOGY, cilt.23, ss.212-220, 2018 (SCI İndekslerine Giren Dergi)

Özet

Objectives: Newer tyrosine kinase inhibitors (TKIs) (bosutinib, ponatinib) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in patients with chronic myeloid leukemia (CML) who failed two lines (imatinib -> nilotinib or imatinib -> dasatinib) of TKI therapy. However, these TKIs are not available in many countries and not all patients can undergo allo-HSCT.